|
Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Suppliers list
|
Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- manufacturers
- β-Aminoarteether
-
- $148.00
-
2026-08-30
- CAS:133162-24-0
- Purity: 96.09%
- Supply Ability: 10g
|
| | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Basic information |
| Product Name: | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- | | Synonyms: | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]-;β-Aminoarteether;SM934 free base;β-Aminoarteether, 10 mM in DMSO;Aminoarteether | | CAS: | 133162-24-0 | | MF: | C17H29NO5 | | MW: | 327.42 | | EINECS: | | | Product Categories: | | | Mol File: | 133162-24-0.mol | ![Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Structure](CAS/20210111/GIF/133162-24-0.gif) |
| | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Chemical Properties |
| Boiling point | 421.0±45.0 °C(Predicted) | | density | 1.20±0.1 g/cm3(Predicted) | | pka | 8.46±0.10(Predicted) | | form | Oil | | color | Light yellow to yellow |
| | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Usage And Synthesis |
| Uses | β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases[1]. | | Definition | ChEBI: Beta-aminoarteether is an artemisinin derivative in which the lactone of (+)-artemisinin has been converted into the corresponding lactol 2-aminoethyl ether [beta (S) configuration at the new stereocentre]. It is an artemisinin derivative and a primary amino compound. | | in vivo | β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice[1]. | Animal Model: | Female NZB/W F1 mice (Six and half months old)[1] | | Dosage: | 1 mg/kg, 3 mg/kg, and 10 mg/kg | | Administration: | Oral administration; daliy; for 3 months | | Result: | Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. |
| | References | [1] Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424. DOI:10.1371/journal.pone.0032424
[2] Yang FM, Fan D, Yang XQ, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2021;42(4):593-603. DOI:10.1038/s41401-020-0484-5 |
| | Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]- Preparation Products And Raw materials |
|